Tyrosine

Tyrosine

SCHEMBL1033972

NC(Cc1ccc(O)cc1)C(=O)O.O=[PH](O)O

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.86
PTGS1 P23219 3/20 0.61
ALPI P09923 1/20 0.61
PKM P14618 1/20 0.61
XIAP P98170 1/20 0.61
ALOX15 P16050 3/20 0.57
HIF1A Q16665 3/20 0.57
KDM4E B2RXH2 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
USP2 O75604 1/20 0.57
EGFR P00533 1/20 0.57
LCK P06239 1/20 0.57
FYN P06241 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
HTR2A P28223 1/20 0.57
PTGS2 P35354 1/20 0.57
RECQL P46063 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TPH1 P17752 1/20 0.53
GRB2 P62993 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL2541964 1.00 SLC7A5 (0.86) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL20787 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11520041 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL10978805 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11676395 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1580 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL638520 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL1581 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL11676367 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL10978820 0.93 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114796520-A anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates 苏特罗生物制药公司 2022-07-29 CN disclosed
CN-109069664-B anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates 苏特罗生物制药公司 2022-05-13 CN disclosed
EP-3401319-B1 CELL CULTURE MEDIA MERCK PATENT GMBH (DE) 2020-07-22 EP disclosed
US-10619131-B2 Cell culture media MERCK PATENT GMBH (DE) 2020-04-14 US disclosed
EP-3401319-A1 CELL CULTURE MEDIA Merck Patent GmbH (DE) 2018-11-14 EP disclosed
US-10030225-B2 Cell culture media MERCK PATENT GMBH (DE) 2018-07-24 US disclosed
EP-2920296-B1 CELL CULTURE MED MERCK PATENT GMBH (DE) 2018-07-18 EP disclosed
CN-105120854-A Novel salicylic acid derivatives, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof UNIV TORONTO 2015-12-02 CN disclosed
US-20150337258-A1 CELL CULTURE MEDIA MERCK PATENT GMBH (DE) 2015-11-26 US disclosed
EP-2920296-A1 CELL CULTURE MED Merck Patent GmbH (DE) 2015-09-23 EP disclosed
CN-101217954-B Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE 2013-07-10 CN disclosed
US-20110263535-A1 TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS UNIVERSITY OF SOUTHERN CALIFORNIA 2011-10-27 US disclosed
WO-2011133963-A2 TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-10-27 WO disclosed
EP-2276510-A2 CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE Human Biomolecular Research Institute (US) 2011-01-26 EP disclosed
WO-2010039163-A2 CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-04-08 WO disclosed
CN-101217954-A Substituted oxazole derivatives and their use as tyrosine kinase inhibitors AB SCIENCE (FR) 2008-07-09 CN disclosed
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed
EP-1259491-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS Abbott Laboratories (US) 2002-11-27 EP disclosed
WO-2001060802-A1 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-08-23 WO disclosed
EP-0526488-A1 BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS. PFIZER (US) 1993-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150337258-A1 CELL CULTURE MEDIA SRC, PTPN4, PTPN6 SLC7A5 423/4885PTGS1 1720/4885ALPI 4397/4885
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A SLC7A5 1841/4885PTGS1 467/4885ALPI 2322/4885
US-10030225-B2 Cell culture media SRC, PTPN4, PTPN6 SLC7A5 423/4885PTGS1 1720/4885ALPI 4397/4885
US-10619131-B2 Cell culture media SRC, PTPN4, PTPN6 SLC7A5 423/4885PTGS1 1720/4885ALPI 4397/4885
US-20110263535-A1 TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS TYMP, MTAP, TK1 SLC7A5 606/4885PTGS1 4608/4885ALPI 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.